2. Cyclacel Pharmaceuticals (CYCC) develops mechanism-targeted drugs for human cancers, targeting the cell cycle in order to slow progression or shrink tumors. Cyclacel's second-quarter loss decreased 44% to $3.9 million, or 18 cents a share, as revenue fell 55%. Cyclacel has $20 million of cash and no debt. Its stock sells for a book value multiple of 4.3, a 19% discount to its peer average. It's expensive based on sales. Just two analysts follow the company, both rating its stock "buy." A median target of $5.25 suggests the stock will more than triple.
Bullish Scenario: Roth Capital Partners values the stock at $7, implying it will more than quadruple.